In last trading session, Arcutis Biotherapeutics Inc (NASDAQ:ARQT) saw 2.35 million shares changing hands with its beta currently measuring 1.66. Company’s recent per share price level of $15.16 trading at -$0.33 or -2.13% at ring of the bell on the day assigns it a market valuation of $1.80B. That closing price of ARQT’s stock is at a discount of -6.86% from its 52-week high price of $16.20 and is indicating a premium of 53.89% from its 52-week low price of $6.99. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 2.35 million shares which gives us an average trading volume of 2.25 million if we extend that period to 3-months.
For Arcutis Biotherapeutics Inc (ARQT), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.25. Splitting up the data highlights that, out of 3 analysts covering the stock, 1 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 2 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.21 in the current quarter.
Arcutis Biotherapeutics Inc (NASDAQ:ARQT) trade information
Upright in the red during last session for losing -2.13%, in the last five days ARQT remained trading in the green while hitting it’s week-highest on Wednesday, 03/12/25 when the stock touched $15.16 price level, adding 5.78% to its value on the day. Arcutis Biotherapeutics Inc’s shares saw a change of 8.83% in year-to-date performance and have moved 2.57% in past 5-day. Arcutis Biotherapeutics Inc (NASDAQ:ARQT) showed a performance of 30.80% in past 30-days. Number of shares sold short was 19.77 million shares which calculate 8.42 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 19 to the stock, which implies a rise of 20.21% to its current value. Analysts have been projecting 19 as a low price target for the stock while placing it at a high target of 19. It follows that stock’s current price would drop -25.33% in reaching the projected high whereas dropping to the targeted low would mean a loss of -25.33% for stock’s current value.
Arcutis Biotherapeutics Inc (ARQT) estimates and forecasts
This year revenue growth is estimated to rise 53.55% from the last financial year’s standing.
6 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 64.1M for the same. And 6 analysts are in estimates of company making revenue of 72.63M in the next quarter. Company posted 49.57M and 30.86M of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -0.98% during past 5 years.
Arcutis Biotherapeutics Inc (NASDAQ:ARQT)’s Major holders
Insiders are in possession of 2.02% of company’s total shares while institution are holding 112.26 percent of that, with stock having share float percentage of 114.57%. Investors also watch the number of corporate investors in a company very closely, which is 112.26% institutions for Arcutis Biotherapeutics Inc that are currently holding shares of the company. JENNISON ASSOCIATES LLC is the top institutional holder at ARQT for having 11.57 million shares of worth $107.62 million. And as of 2024-06-30, it was holding 9.3712 of the company’s outstanding shares.
The second largest institutional holder is SUVRETTA CAPITAL MANAGEMENT, LLC, which was holding about 10.0 million shares on 2024-06-30. The number of shares represents firm’s hold over 8.1021 of outstanding shares, having a total worth of $93.04 million.
On the other hand, Vanguard Total Stock Market Index Fund and PGIM Jennison Small Company Fd are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 3.23 shares of worth $48.94 million or 2.72% of the total outstanding shares. The later fund manager was in possession of 3.09 shares on Dec 31, 2024 , making its stake of worth around $46.77 million in the company or a holder of 2.60% of company’s stock.
